These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37303671)

  • 1. Correlation analysis of the expression of mesenchymal circulating tumor cells and CD133 with the prognosis of colorectal cancer.
    Zhou H; Shen H; Xiang F; Yang X; Li R; Zeng Y; Liu Z
    Am J Transl Res; 2023; 15(5):3489-3499. PubMed ID: 37303671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of epithelial-mesenchymal transition typing of circulating tumour cells in colorectal cancer.
    Hou J; Guo C; Lyu G
    Colorectal Dis; 2020 May; 22(5):581-587. PubMed ID: 31868956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRL-3 and MMP9 Expression and Epithelial-Mesenchymal Transition Markers in Circulating Tumor Cells From Patients With Colorectal Cancer: Potential Value in Clinical Practice.
    Hong XC; Liang QL; Chen M; Yang HX; Huang J; Yi SL; Wang ZW; Liang HY; Zhang DY; Huang ZY
    Front Oncol; 2022; 12():878639. PubMed ID: 35574414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesenchymal circulating tumor cells and Ki67: their mutual correlation and prognostic implications in hepatocellular carcinoma.
    Yang X; Ni H; Lu Z; Zhang J; Zhang Q; Ning S; Qi L; Xiang B
    BMC Cancer; 2023 Jan; 23(1):10. PubMed ID: 36600214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of CTCs and CSCs of tumor drainage vein blood in Dukes' stage B and C colorectal cancer patients.
    Shimada R; Iinuma H; Akahane T; Horiuchi A; Watanabe T
    Oncol Rep; 2012 Apr; 27(4):947-53. PubMed ID: 22267181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis.
    Wang W; Wan L; Wu S; Yang J; Zhou Y; Liu F; Wu Z; Cheng Y
    Cell Oncol (Dordr); 2018 Oct; 41(5):495-504. PubMed ID: 29949050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and Therapeutic Significance of Circulating Tumor Cell Phenotype Detection Based on Epithelial-Mesenchymal Transition Markers in Early and Midstage Colorectal Cancer First-Line Chemotherapy.
    Lu G; Lu Z; Li C; Huang X; Luo Q
    Comput Math Methods Med; 2021; 2021():2294562. PubMed ID: 34777560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor cells as an independent prognostic factor in advanced colorectal cancer: a retrospective study in 121 patients.
    Wang L; Zhou S; Zhang W; Wang J; Wang M; Hu X; Liu F; Zhang Y; Jiang B; Yuan H
    Int J Colorectal Dis; 2019 Apr; 34(4):589-597. PubMed ID: 30627849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
    Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
    World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Significance of Mesenchymal Circulating Tumor Cells in Patients With Oligometastatic Hormone-Sensitive Prostate Cancer Who Underwent Cytoreductive Radical Prostatectomy.
    Yang G; Xie J; Zhang S; Gu W; Yuan J; Wang R; Guo C; Ye L; Peng B; Yao X; Yang B
    Front Oncol; 2021; 11():812549. PubMed ID: 35127528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelial-to-mesenchymal transition of circulating tumor cells and CD133 expression on predicting prognosis of thyroid cancer patients.
    Li D; Li N; Ding Y
    Mol Clin Oncol; 2022 Sep; 17(3):141. PubMed ID: 36033974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between mesenchymal circulating tumor cells and prognosis of urologic malignancies: a single-center retrospective analysis.
    Wang L; Ding D
    Am J Transl Res; 2023; 15(1):502-510. PubMed ID: 36777844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer.
    Guan X; Li C; Li Y; Wang J; Yi Z; Liu B; Chen H; Xu J; Qian H; Xu B; Ma F
    Front Oncol; 2021; 11():602222. PubMed ID: 34150608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor cell enumeration for improved screening and disease detection of patients with colorectal cancer.
    Tsai WS; Hung WS; Wang TM; Liu H; Yang CY; Wu SM; Hsu HL; Hsiao YC; Tsai HJ; Tseng CP
    Biomed J; 2021 Dec; 44(6 Suppl 2):S190-S200. PubMed ID: 35292267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
    Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
    J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of CD133-positive circulating tumor cells predicts worse progression-free survival in patients with metastatic castration-sensitive prostate cancer.
    Yang Y; Liu Z; Wang Q; Chang K; Zhang J; Ye D; Kong Y; Dai B
    Int J Urol; 2022 May; 29(5):383-389. PubMed ID: 35102615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation.
    Das A; Kunkel M; Joudeh J; Dicker DT; Scicchitano A; Allen JE; Sarwani N; Yang Z; Kaifi J; Zhu J; Liao J; El-Deiry WS
    Cancer Biol Ther; 2015; 16(5):709-13. PubMed ID: 25806877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between the Epithelial-Mesenchymal Transition Phenotypes of Circulating Tumor Cells and the Clinicopathological Features of Patients with Colorectal Cancer.
    Wu F; Zhu J; Mao Y; Li X; Hu B; Zhang D
    Dis Markers; 2017; 2017():9474532. PubMed ID: 29430076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor microemboli (CTM) and vimentin+ circulating tumor cells (CTCs) detected by a size-based platform predict worse prognosis in advanced colorectal cancer patients during chemotherapy.
    Zhang D; Zhao L; Zhou P; Ma H; Huang F; Jin M; Dai X; Zheng X; Huang S; Zhang T
    Cancer Cell Int; 2017; 17():6. PubMed ID: 28070168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.